免疫检查点抑制剂治疗癌症患者非新生血管性AMD风险降低
这项回顾性倾向匹配队列研究基于TriNetX全球协作网络,纳入60岁以上有癌症史的存活患者,比较接受与未接受免疫检查点抑制剂(ICI)治疗者5年内AMD发病率。匹配后每组36,037例,ICI治疗者非新生血管性AMD风险显著降低(HR 0.77;95%CI 0.63-0.93;
要点
- ICI治疗与老年癌症患者非新生血管性AMD风险降低相关(HR 0.77)。
- ICI暴露与新生血管性AMD无显著关联。
- 黑色素瘤及转移性疾病亚组中保护性关联持续存在。
核心结论
- 在大型多中心队列中,ICI治疗与老年癌症患者非新生血管性AMD风险降低相关。
- 提示T细胞调节可能在AMD发病机制中具有潜在保护作用,需进一步研究ICI对视网膜的影响。
研究设计与样本
- 回顾性队列研究,数据来自TriNetX全球协作网络,纳入60岁以上有癌症史且随访期间存活的患者。
- 构建接受ICI与未接受ICI两个队列,按人口学和临床协变量进行1:1倾向评分匹配。
- 采用Kaplan-Meier估计和Cox比例风险模型评估ICI暴露与5年AMD发病率的关联。
主要发现
- 匹配后每组36,037例患者。
- ICI暴露与新生血管性AMD无显著关联。
- 黑色素瘤和转移性疾病亚组中保护性关联持续存在。
临床怎么用
- 对于老年癌症患者,ICI治疗可能与降低非新生血管性AMD风险相关,眼科随访中可关注这一潜在获益信号。
局限性
- 回顾性研究设计。
- 仅纳入随访期间存活的患者。
- 需进一步研究验证ICI对视网膜的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate whether immune checkpoint inhibitors (ICIs), which modulate T-cell activity in cancer therapy, influence the risk of developing age-related macular degeneration (AMD). DESIGN: Retrospective cohort study. PARTICIPANTS: Adults aged ≥60 years with a history of cancer, identified from the TriNetX Global Collaborative Network. Only patients who remained alive throughout the follow-up period were included. METHODS: Two cohorts were constructed: patients who received ICIs and those who did not. Sub-analyses were conducted for patients with melanoma and for those with metastatic disease. Propensity score matching (1:1) was performed using demographic and clinical covariates. Kaplan-Meier estimates and Cox proportional hazards models assessed the association between ICI exposure and AMD incidence over 5 years. MAIN OUTCOME MEASURES: Incidence of non-neovascular and neovascular AMD after ICI therapy. RESULTS: After matching, 36,037 patients were included in each cohort. ICI-treated patients had a significantly lower risk of developing non-neovascular AMD (hazard ratio [HR], 0.77; 95% CI, [0.63, 0.93]; log-rank P = .0084) over a 5-year follow-up. No significant association was observed between ICI exposure and neovascular AMD. The protective association persisted in melanoma and metastatic subgroups. CONCLUSIONS: In this large, multicenter cohort, ICI therapy was associated with a reduced risk of non-neovascular AMD in older adults with cancer. These findings suggest a potential protective role of T-cell modulation in AMD pathogenesis and highlight the need for further research into the retinal effects of ICIs.
引用
- Lishinsky-Fischer N, Gharra S, Nitzan I, et al. Reduced Risk of Non-Neovascular AMD in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Propensity-Matched Cohort Study. Am J Ophthalmol. 2026. PMID: 41512983. doi:10.1016/j.ajo.2025.12.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。